AJ

Anshu Jain

Director Director DIN 06631866
DIN 06631866 First appointment Sep 2013 Primary industry Trading
Unlock full profile Investments · shareholding · contact details
Past companies 2 historical roles
Total affiliations 2 Since Sep 2013
Shareholding value •••• Premium profile

About Anshu Jain

Data last updated:

Anshu Jain was a Director at Aarav Maladies Pharma Services Private Limited (2017–2018) and Director at Anim Dezire Private Limited (2013–2014). The companies operate in Trading and Business Services.

DIN 06631866
Primary Designation Director
Industry Trading
First Appointment 05 Sep 2013

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director05 Jun 20172017Active
Anim Dezire Private Limited U74900DL2013PTC257221
Director05 Sep 20132013Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Aarav Maladies Pharma Services Private Limited
Anim Dezire Private Limited
Premium access

Shareholding and investment profile for Anshu Jain

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Anshu Jain

Anshu Jain was first appointed on 05 Sep 2013 as Director at Anim Dezire Private Limited. The most recent appointment on record is 05 Jun 2017 at Aarav Maladies Pharma Services Private Limited.

Anshu Jain held 2 earlier board appointments: Aarav Maladies Pharma Services Private Limited (Director, 05 Jun 2017 to 25 May 2018); Anim Dezire Private Limited (Director, 05 Sep 2013 to 25 Jul 2014).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available